Exelixis Inc (EXEL) Stock Price, Quote & News

Company Profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosin...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 837 7000

Fax: 650 837 8300

Website: www.exelixis.com

Address:

1851 Harbor Bay Parkway, Alameda, United States

justiceforb_85 Feb. 3 at 4:09 AM

$EXEL look forward to approval of zanzalintinib in mCRC.

0 · Reply

OtherOtttawaGuy Feb. 2 at 1:13 PM

$EXEL February 2, 2026 8:00 AM EST Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

0 · Reply

zman94 Jan. 30 at 12:06 AM

https://seekingalpha.com/article/4863640?gt=3c24ee2b4ec986b3 $EXEL

0 · Reply

SuperGreenToday Jan. 29 at 11:02 AM

$EXEL Share Price: $42.67 Contract Selected: Aug 21, 2026 $45 Calls Buy Zone: $4.13 – $5.10 Target Zone: $6.87 – $8.40 Potential Upside: 57% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BillionerOfKing Jan. 24 at 5:27 PM

$EXEL Current Stock Price: $44.27 Contracts to trade: $45 EXEL Feb 20 2026 Call Entry: $1.40 Exit: $2.62 ROI: 87% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

AdamURAtoFookingNeptune Jan. 23 at 7:52 PM

$EXEL $INCY small trims here

0 · Reply

BioTechHealthX Jan. 23 at 5:48 PM

$EXEL While hype-driven biotech stocks burn cash, Exelixis stock keeps delivering real oncology revenue. Here’s why NASDAQ: EXEL is quietly becoming a long-term winner. https://biotechhealthx.com/biotech-news/exelixis-exel-isnt-a-flashy-biotech-its-the-one-quietly-making-billions/

0 · Reply

StockBraker Jan. 23 at 1:34 PM

$EXEL If this gets below $40 it is worth starting a position. I'll be rebuying. HODLing for $65+.

1 · Reply

justiceforb_85 Jan. 23 at 4:03 AM

$EXEL might be worth a buy considering NDA for zanzalintinib this year and partnership in CRC with $NTRA.

0 · Reply

Pfreakstocks Jan. 16 at 4:52 PM

$EXEL 😭

0 · Reply

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

Jan 28, 2026, 10:06 PM EST - 5 days ago

Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval

Jan 27, 2026, 4:05 PM EST - 6 days ago

Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026

Jan 22, 2026, 7:22 AM EST - 12 days ago

Exelixis: High-Growth Oncology Name Trading At A Discount

Jan 13, 2026, 12:45 AM EST - 21 days ago

Exelixis, Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 4:00 PM EST - 22 days ago

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Jan 7, 2026, 8:00 AM EST - 27 days ago

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

NTRA

Jan 6, 2026, 4:05 PM EST - 27 days ago

Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026

Dec 31, 2025, 12:46 PM EST - 4 weeks ago

See How Rare Bullish Inflows Lift Outliers Like Exelixis

Dec 11, 2025, 6:12 AM EST - 7 weeks ago

Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript

Dec 3, 2025, 4:05 PM EST - 2 months ago

Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025

Nov 10, 2025, 1:41 PM EST - 3 months ago

Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 6, 2025, 9:39 PM EST - 3 months ago

Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still

Nov 6, 2025, 4:05 PM EST - 3 months ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

Nov 4, 2025, 9:06 PM EST - 3 months ago

Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:05 PM EST - 3 months ago

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 21, 2025, 4:05 PM EDT - 3 months ago

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Oct 20, 2025, 10:48 AM EDT - 3 months ago

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results

Oct 20, 2025, 2:30 AM EDT - 3 months ago

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

Oct 18, 2025, 3:00 AM EDT - 3 months ago

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

Sep 24, 2025, 12:33 PM EDT - 4 months ago

Exelixis, Inc. (EXEL) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 10:20 AM EDT - 5 months ago

Exelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 9, 2025, 1:06 PM EDT - 5 months ago

Exelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 10:06 AM EDT - 5 months ago

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm

Sep 3, 2025, 7:43 PM EDT - 5 months ago

Exelixis, Inc. (EXEL) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 3:43 PM EDT - 5 months ago

Exelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)

Aug 29, 2025, 5:47 PM EDT - 5 months ago

Exelixis Announces Appointment of Dana T. Aftab, Ph.D.

Aug 27, 2025, 4:05 PM EDT - 5 months ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

Aug 25, 2025, 6:01 PM EDT - 5 months ago

Exelixis: RCC Stronghold, NET Launch, And A CRC Readout That Matters

Jul 31, 2025, 12:27 PM EDT - 6 months ago

Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards

Jul 29, 2025, 12:32 PM EDT - 6 months ago

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans

Jul 28, 2025, 10:51 PM EDT - 6 months ago

Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript

Jul 28, 2025, 4:05 PM EDT - 6 months ago

Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 24, 2025, 5:04 PM EDT - 6 months ago

Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Jul 14, 2025, 4:05 PM EDT - 7 months ago

Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025

Jun 23, 2025, 12:58 PM EDT - 8 months ago

Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment

Jun 23, 2025, 10:37 AM EDT - 8 months ago

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

Jun 22, 2025, 5:00 PM EDT - 8 months ago

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

Jun 20, 2025, 6:54 AM EDT - 8 months ago

Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

May 23, 2025, 6:25 AM EDT - 9 months ago

Product Performance, Big Money Lift Exelixis

May 22, 2025, 5:17 PM EDT - 9 months ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

May 22, 2025, 4:05 PM EDT - 9 months ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

May 14, 2025, 2:53 PM EDT - 9 months ago

Exelixis: A Notable Quarter

May 14, 2025, 10:44 AM EDT - 9 months ago

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

May 13, 2025, 8:31 PM EDT - 9 months ago

Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript

May 13, 2025, 6:06 PM EDT - 9 months ago

Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

May 13, 2025, 4:07 PM EDT - 9 months ago

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

justiceforb_85 Feb. 3 at 4:09 AM

$EXEL look forward to approval of zanzalintinib in mCRC.

0 · Reply

OtherOtttawaGuy Feb. 2 at 1:13 PM

0 · Reply

zman94 Jan. 30 at 12:06 AM

https://seekingalpha.com/article/4863640?gt=3c24ee2b4ec986b3 $EXEL

0 · Reply

SuperGreenToday Jan. 29 at 11:02 AM

0 · Reply

BillionerOfKing Jan. 24 at 5:27 PM

0 · Reply

AdamURAtoFookingNeptune Jan. 23 at 7:52 PM

$EXEL $INCY small trims here

0 · Reply

BioTechHealthX Jan. 23 at 5:48 PM

0 · Reply

StockBraker Jan. 23 at 1:34 PM

$EXEL If this gets below $40 it is worth starting a position. I'll be rebuying. HODLing for $65+.

1 · Reply

justiceforb_85 Jan. 23 at 4:03 AM

$EXEL might be worth a buy considering NDA for zanzalintinib this year and partnership in CRC with $NTRA.

0 · Reply

Pfreakstocks Jan. 16 at 4:52 PM

$EXEL 😭

0 · Reply

BillionerOfKing Jan. 15 at 12:11 AM

$EXEL Current Stock Price: $45.23 Contracts to trade: $45 EXEL Jan 16 2026 Call Entry: $0.20 Exit: $0.28 ROI: 39% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

OtherOtttawaGuy Jan. 14 at 9:15 PM

$EXEL Let's see what happens at $46...

1 · Reply

inv1ncible Jan. 14 at 3:17 AM

$TGTX this stock reminds me of $EXEL . Stuck at same prices for years then boom $40’s

0 · Reply

ZacksResearch Jan. 12 at 7:30 PM

$EXEL misses revenue estimates for 2025 — what's next for the stock? 🤔 Despite strong sales of Cabometyx, preliminary revenues of $2.32B fell short of the Zacks Consensus Estimate of $2.33B. With a promising pipeline, including zanzalintinib, and plans to expand market presence, $EXEL is gearing for growth in 2026. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2815675/exelixis-posts-preliminary-25-results-issues-26-outlook?cid=sm-stocktwits-2-2815675-body-28518&ADID=SYND_STOCKTWITS_TWEET_2_2815675_BODY_28518

1 · Reply

ZacksResearch Jan. 12 at 6:30 PM

$EXEL just put real numbers on the board — and the next phase is taking shape. 👀 EXEL posted approximately $2.32B in 2025 revenues and guided $2.525–$2.625B for 2026, driven by continued Cabometyx growth and an advancing zanzalintinib NDA. Full outlook and what’s driving the 2026 setup 👉 https://www.zacks.com/stock/news/2815675/exelixis-posts-preliminary-25-results-issues-26-outlook?cid=sm-stocktwits-2-2815675-teaser-28517&ADID=SYND_STOCKTWITS_TWEET_2_2815675_TEASER_28517

0 · Reply

OtherOtttawaGuy Jan. 12 at 12:25 AM

$EXEL Fiscal Year 2025 Fiscal Year 2026 Guidance Total revenues ~ $2.320 billion $2.525 billion - $2.625 billion Net product revenues ~ $2.123 billion $2.325 billion - $2.425 billion(1) Cost of goods sold, % of net product revenues ~ 3.7% 3.5% - 4.5% Research and development expenses ~ $825 million(2) $875 million - $925.X million(3) Selling, general and administrative expenses ~ $520 million(4) $575 million - $625 million(5) Effective tax rate n/a(6) 21% - 23% Ending cash and marketable securities(7) ~ $1.65 billion n/p

0 · Reply

OtherOtttawaGuy Jan. 12 at 12:25 AM

$EXEL 2025 Fidcal Year Results Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion – – Presentation and webcast at J.P. Morgan 2026 Healthcare Conference tomorrow, Monday, January 12th at 5:15 p.m. PT / 8:15 p.m. ET –

0 · Reply

DefenseMania Jan. 10 at 5:02 PM

$EXEL imo EXEL is very likely to be acquired this year , of course imo 😉

0 · Reply

Jblack500 Jan. 9 at 3:04 PM

$BBIO $INCY $MRK $EXEL $ABVX GILD MRK ABBV BMY CRDF ELAN the 11 names in my biotech basket (elan animal health)

0 · Reply

ZacksResearch Jan. 8 at 5:32 PM

Is $EXEL's zanzalintinib the next big thing in oncology? 🚀 With a promising phase III study expected to start in mid-2026 and a new drug application submitted for metastatic CRC, Exelixis is positioning zanzalintinib as a potential game-changer. Their collaboration with $NTRA could reshape MRD-guided therapies. Discover the full potential here 👉 https://www.zacks.com/stock/news/2814082/exel-collaborates-with-natera-for-late-stage-colorectal-cancer-study?cid=sm-stocktwits-2-2814082-body-28037&ADID=SYND_STOCKTWITS_TWEET_2_2814082_BODY_28037

0 · Reply

ZacksResearch Jan. 8 at 4:32 PM

$EXEL makes a late-stage move — and the stock is reacting 🧬 Exelixis teamed up with Natera on the phase III STELLAR-316 study, testing zanzalintinib in resected stage II/III colorectal cancer, and shares moved higher on the news. Get the full details on the collaboration here 👉 https://www.zacks.com/stock/news/2814082/exel-collaborates-with-natera-for-late-stage-colorectal-cancer-study?cid=sm-stocktwits-2-2814082-teaser-28035&ADID=SYND_STOCKTWITS_TWEET_2_2814082_TEASER_28035

0 · Reply

OtherOtttawaGuy Jan. 8 at 3:51 PM

$EXEL It just needs to break through that $46 level and stay above.

0 · Reply

Market Cap	11.09B
Revenue (ttm)	2.17B
Net Income (ttm)	521.27M
EPS (ttm)	N/A
PE Ratio	18.15
Forward PE	14.90
Profit Margin	24.04%
Debt to Equity Ratio	0.00

Volume	4,146,500
Avg Vol	2,567,424
Day's Range	N/A - N/A
Shares Out	268.11M
Stochastic %K	47%
Beta	0.40
Analysts	Sell
Price Target	$45.61